Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Alebund Pharmaceuticals (Jiangsu) Days Inventory?
Alebund Pharmaceuticals (Jiangsu)HKSE:09637 -2.87%5 Days Inventory is 172.58 as of Dec. 2025, which is 52% below its 10-year median of 355.94. GuruFocus rates HKSE:09637 with a GF Score™ of 5/100. The stock has 1 warning sign investors should review. Among 920 Drug Manufacturers companies, Alebund Pharmaceuticals (Jiangsu) ranks worse than 53.59% on this metric.
The historical rank and industry rank for Alebund Pharmaceuticals (Jiangsu)'s Days Inventory or its related term are showing as below:
HKSE:09637'
s Days Inventory Range Over the Past 10 Years
Min: 172.58 Med: 355.94 Max: 539.29
Current: 172.58
During the past 2 years, Alebund Pharmaceuticals (Jiangsu)'s highest Days Inventory was 539.29. The lowest was 172.58. And the median was 355.94.
HKSE:09637's Days Inventory is ranked worse than 53.59% of 920
companies
in the Drug Manufacturers industry
Industry Median: 164.815
vs HKSE:09637: 172.58
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Alebund Pharmaceuticals (Jiangsu)'s Inventory Turnover for the
six
months ended in Dec. 2025 was 2.11.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Alebund Pharmaceuticals (Jiangsu)'s Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.26.
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Alebund Pharmaceuticals (Jiangsu)'s Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Alebund Pharmaceuticals (Jiangsu)'s Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Alebund Pharmaceuticals (Jiangsu) Days Inventory Related Terms
Alebund Pharmaceuticals (Jiangsu) Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alebund Pharmaceuticals (Jiangsu) Days Inventory Chart
Alebund Pharmaceuticals (Jiangsu) Annual Data
Trend
Dec24
Dec25
Days Inventory
539.29
172.58
Alebund Pharmaceuticals (Jiangsu) Semi-Annual Data
Dec24
Dec25
Days Inventory
539.29
172.58
HKSE:09637 vs LLY, JNJ, ABBV: Days Inventory Comparison
For the Drug Manufacturers - General subindustry, Alebund Pharmaceuticals (Jiangsu)'s Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alebund Pharmaceuticals (Jiangsu) Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alebund Pharmaceuticals (Jiangsu)'s Days Inventory distribution charts can be found below:
* The bar in red indicates where Alebund Pharmaceuticals (Jiangsu)'s Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a Days Inventory of 172.58 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors. This is 52% below median its historical median of 355.94. Over the past decade, Alebund Pharmaceuticals (Jiangsu)'s Days Inventory has ranged from 172.58 to 539.29. According to the industry distribution chart, Alebund Pharmaceuticals (Jiangsu) ranks #493 out of 920 companies in the Drug Manufacturers industry, placing it in the top 53.6%.
Is Alebund Pharmaceuticals (Jiangsu)'s Days Inventory too high?
Alebund Pharmaceuticals (Jiangsu)'s current Days Inventory of 172.58 is 52% below median its 10-year median of 355.94. Over the past 10 years, this metric has ranged from a low of 172.58 to a high of 539.29. The Drug Manufacturers industry median Days Inventory is 164.82. Alebund Pharmaceuticals (Jiangsu)'s value of 172.58 is 4.7% above this industry median. Based on the distribution chart, Alebund Pharmaceuticals (Jiangsu) ranks #493 out of 920 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Alebund Pharmaceuticals (Jiangsu) has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Alebund Pharmaceuticals (Jiangsu)'s Days Inventory compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Alebund Pharmaceuticals (Jiangsu) ranks #493 out of 920 companies for Days Inventory. This places Alebund Pharmaceuticals (Jiangsu) in the lower half of its industry. The industry median Days Inventory is 164.82. Alebund Pharmaceuticals (Jiangsu)'s value of 172.58 is 4.7% above this benchmark. Historically, Alebund Pharmaceuticals (Jiangsu)'s own Days Inventory has ranged from 172.58 to 539.29 over the past decade. While the company's 10-year median is 355.94 vs. the industry median of 164.82, Alebund Pharmaceuticals (Jiangsu) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.82, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alebund Pharmaceuticals (Jiangsu)'s current Days Inventory of 172.58 is 4.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Alebund Pharmaceuticals (Jiangsu) and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alebund Pharmaceuticals (Jiangsu)'s current Days Inventory is 172.58, which is 52% below median its own 10-year median of 355.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alebund Pharmaceuticals (Jiangsu) stock overvalued right now?
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a current Days Inventory of 172.58. The current Days Inventory is 172.58, which is 52% below median its 10-year median of 355.94 and 4.7% above the Drug Manufacturers industry median of 164.82. Alebund Pharmaceuticals (Jiangsu)'s overall GF Score™ is 5/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Alebund Pharmaceuticals (Jiangsu) (HKSE:09637), the current Days Inventory is 172.58 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alebund Pharmaceuticals (Jiangsu) Ltd is a biopharmaceutical company. Along with its subsidiaries, the company is principally engaged in the development, manufacturing, and commercialization of renal products. Its product portfolio in clinical and preclinical stages consists of one Core Product AP301 and six other product candidates, including one late-clinical-stage product candidate AP306, one early-clinical-stage product candidate (AP303), and four preclinical product candidates (AP308, AP304, AP305, and AP307). The company generated revenue from the sales of Mircera in China, a product used in the treatment of renal anemia.
5GF Score
Get the complete analysis for HKSE:09637
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09637 has been successfully added to your 
